NCT04371146View on ClinicalTrials.gov

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

February 13, 2020

Study Completion Date

February 13, 2020

Conditions
Healthy
Interventions
DRUG

Methylphenidate

35 mg methylphenidate (Ritalin®) is administered once using a randomized placebo-controlled between subject's design

DRUG

Reboxetine

8 mg Reboxetine (Edronax®) is administered once using a randomized placebo-controlled between subject's design

DRUG

Placebos

A placebo pill is administered once using a randomized placebo-controlled between subject's design

Trial Locations (1)

8006

University of Zurich, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT04371146 - The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making | Biotech Hunter | Biotech Hunter